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Abstract 
Tulbaghia violacea William Henry Harvey (Harv. Alliaceae) is a small bulbous herb belonging to the 
family Alliaceae. It is used in South Africa to treat fever, colds, asthma, paralysis, and hypertension. 
Meanwhile, cardiovascular disease accounts for about 30 % of total global death, with most of these 
deaths occurring in low and middle-income countries. Furthermore, people in low-income countries are 
still largely dependent on plants in their surroundings for both prophylaxis and treatment of diseases, 
partly due to limited access to and cost of pharmaceuticals, and folkloric evidence of the potency of 
medicinal plants and/or local belief systems. Therefore, the present review aims to proffer possible ways 
by which T. violacea may improve cardiovascular outcomes. An extensive and systematic review of the 
literature was carried out, and relevant findings presented in this review. There is evidence that T. 
violacea may modulate the renin-angiotensin system, the autonomic nervous system, oxidative stress 
and haemostasis, with resultant protection of the cardiovascular system in both health and disease.  
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INTRODUCTION 
 
Cardiovascular disease (CVD) is a complex 
multi-factorial disease [1]. It accounts for 29.2 % 
of total global deaths, with approximately 80 % of 
these deaths occurring in low and middle-income 
countries [2]. Epidemiologic studies indicate that 
hypertension (HTN), elevated serum lipids, 
increased plasma fibrinogen and coagulation 
factors, increased platelet activation, alterations 
in glucose metabolism (diabetes mellitus, DM), 
and smoking are factors positively associated 
with CVD [3]. Sixty per cent of the burden of CVD 
and about 50 % of that of coronary heart disease 
(CHD) globally is caused by HTN [3].  Age [4], 
gender [5], urbanization [6], obesity [7] and 
certain dietary factors [8] strongly influence the 
occurrence of essential HTN. Although, some of 
the present chemical drugs have shown a lot of 
promise in the treatment of HTN, many patients 
usually need to use a combination of agents from 
the different classes of antihypertensive agents 
presently in the market to achieve the desired 
therapeutic goals, leading to problems with 
adherence to therapeutic regimes [9]. 
Furthermore, uncontrolled blood pressure (BP) 
has also been reported in a high number of 
hypertensive patients who adhere to the 
available antihypertensive drugs and/or therapy 
[10], given impetus to intensive research towards 
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discovering better, cheaper and equally effective 
medicines, including herbs [11].  
 
PLANTS IN CARDIOVASCULAR DISEASE  
 
Plants have formed the basis of sophisticated 
traditional medicine systems that have been in 
existence for thousands of years and continue to 
provide mankind with new remedies, and about 
80 % of the population of the world may still rely 
on plant-derived medicines for their healthcare 
needs [12]. In recent times, there has been a 
rekindling of interest in ‘rediscovering natural 
products’ [13]. Previous works on medicinal 
plants led to the isolation of early drugs such as 
cocaine, codeine, digitoxin, quinine, diosgenin, 
reserpine, pilocarpine and morphine [12]. Some 
plants which have been previously reported to 
have potential beneficial effects against CVD 
include Allium sativum (garlic) [14], Rauwolfia 
serpentina (Apocynaceae) Radix rauwolfiae 
(snake-root) [15], Curcuma longa (turmeric) [16], 
Crataegus monogyna (Hawthorn) and Crataegus 
laevigata (Hawthorn thorny) leaves, flowers and 
berries [17], Salvia miltiorrhiza (red sage, 
Danshen) [18], Ocimum gratissimum L. 
(Labiatae) [19], Andrographis paniculata [20], 
and Tulbaghia violacea [21-23]. The list is 
endless, however this review will be geared 
towards one of such plant: T. violacea. 
 
Tulbaghia violacea 
 
Tulbaghia violacea Harv. (Alliaceae) is a small 
bulbous herb, with attractive purple flowers, 
arising from a white fleshy stalk (figure 1 below). 
It belongs to the same family as onions and 
garlic, Alliaceae. The plant is widespread 
throughout Africa, with the greatest concentration 
in Southern Africa, where it is known locally as 
wilde knoffel (Afrikaans), isihaqa (Zulu) or itswele 
lomlambo (Xhosa) [24]. It is widely used as 
herbal remedy for various ailments such as fever, 
colds, asthma, tuberculosis, rheumatism, 
paralysis, HTN, stomach problems and 
oesophageal cancer; with its leaves and bulbs 
being the parts most commonly used. However, 
adverse effects such as gastroenteritis, 
abdominal pain, acute inflammation, sloughing of 
the intestinal mucosa, contraction of the pupils, 
as well as fatalities has also been reported with 
treatment with extracts of the plant [23,24]. 
 
T. violacea has been postulated to have similar 
secondary metabolites and hence biological 
activities as garlic since they belong to the same 
family; and both have the characteristic sulphur 
smell associated with garlic [23,24].  Sulphur 
compounds have been isolated from both garlic 
and T. violacea, and are credited with the 
medicinal properties of garlic [25,26]. These 
sulphur-containing compounds are produced 
when alliinase, an enzyme present in all plants 
belonging to the Allium species, reacts with alliin 
when the plant is bruised/ crushed [25]. 
Numerous odour forming compounds [25,26] and 
bioflavonoids such as quercetin [27] have also 
been isolated from extracts of T. violacea. The 
optimum pH for activity of alliinase from both 
garlic and T. violacea is 6.5, and that for onion 8 
[28]. 
 
 
 
 
           Figure 1: Tulbaghia violacea (with green leaves and purple flowers) 
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There is extensive clinical, epidemiological, in-
vivo and in-vitro research on the beneficial 
effects of garlic on the cardiovascular system 
(CVS) [14]. However, there are only a few in-vivo 
and in-vitro reports in literature for T. violacea 
and these are due to a recent burst of research 
into it [11,21,22,29-33]. The present review will 
discuss the possible modulatory action of T. 
violacea on the renin-angiotensin aldosterone 
system, the autonomic nervous system, oxidative 
stress and haemostasis and the beneficial effects 
for cardiovascular diseases. 
 
Effects of TV on the renin angiotensin 
aldosterone system 
 
The renin angiotensin aldosterone system 
(RAAS) is a key physiologic regulator of vascular 
tone, salt and water balance, blood pressure 
(BP), bradykinin system and pituitary gland 
hormones [34]. Chronic activation of the RAAS 
results in HTN, vascular and myocardial 
hypertrophy, left ventricular remodelling, 
atherosclerosis , and glomerulosclerosis [34]. T. 
violacea has been reported to display 
angiotensin converting enzyme (ACE) inhibitory 
activity in vitro [31] and in vivo [11,22,32,33]. 
Extracts of T. violacea have been reported to 
reduce systolic blood pressure (SBP) in 
response to infusion of ang I  in anaesthetized 
male spontaneously hypertensive Wistar rats 
(SHR) [11,21] and in normotensive male Wistar 
rats [33] when compared to the corresponding 
values in the control rat groups in acute 
experiments. A similar finding was replicated in 
chronic experiments involving Dahl salt sensitive 
rats (DSS) [22,32], but not in SHR [21] (Table 1, 
Figure 2). 
 
Angiotensin II (ang II) is the most powerful 
biologically active product of the RAAS. It directly 
constricts vascular smooth muscle (VSM) and 
the cells (VSMCs), enhances myocardial 
contractility, stimulates aldosterone production, 
blunts the baroreflex, stimulates the release of 
catecholamines from the adrenal medulla and 
sympathetic nerve endings, increases 
sympathetic nervous system activity, stimulates 
thirst and salt appetite, and increases sodium  
and water reabsorption. It also induces 
inflammation, cell growth, mitogenesis, 
apoptosis, migration, and differentiation, 
regulates the gene expression of bioactive 
substances, reactive oxygen species, and 
activates multiple intracellular signalling 
pathways [38,39]. Consequently, ang II plays an 
important role in atherosclerosis, with most of its 
hypertensinogenic actions mediated through the 
angiotensin II type 1 (AT1) receptor; although an 
angiotensin II type 2 (AT2) receptor exists [34]. 
The lack of a significant change in final BP 
values obtained with co-infusion of T. violacea 
and ang II, when compared to the infusion of ang 
II alone in the SHR in the study conducted by 
Raji et al [11] may suggest that T. violacea
 
Table 1: Cardiovascular effects of Tulbaghia violacea extracts  
 
Reference 
number 
Animal 
used 
Type of 
study 
Plant 
part 
Plant 
preparation 
Results 
[35] N/A in-vitro Leaf, 
Roots 
Aqueous & 
Methanol 
ACE inhibition 
[24] N/A in-vitro Leaf, 
Bulb 
Aqueous & 
methanol 
Anticoagulant & antithrombotic activities 
[36] N/A in-vivo Whole 
plant 
Aqueous 
 
Antioxidant activity 
[33] NWR in-vitro 
in-vivo 
Leaf Aqueous & 
methanol 
ACE inhibition; reduction in MAP 
[29] N/A in-vitro Bulb Methanol Anticoagulant & antithrombotic activities 
[32] DSS in-vivo Leaf Aqueous Reduction in AT1a mRNA expression & 
SBP; increased diuresis & natriuresis 
[37] NWR in-vivo Root Methanol Antioxidant activity 
[30] DIATR in-vivo Root Methanol Improved lipid profile & antioxidant activity 
[11] SHR in-vivo Leaf Methanol Reduced SBP, MAP, DBP & HR; ACE 
inhibition & β1 adrenoceptor blockade 
[22] DSS in-vivo Root Methanol Decrease SBP; increased diuresis & 
natriuresis 
[21] SHR in-vivo Leaf Methanol Reduced plasma aldosterone levels, SBP, 
MAP, DBP & HR; stimulated muscarinic 
receptors 
NWR; normotensive Wistar rats, DIATR; diet-induced atherosclerogenic rats, DSS; Dahl salt sensitive rats, ACE; 
angiotensin converting enzyme, AT1a mRNA; angiotensin II type 1a mRNA, SBP; systolic blood pressure, MAP; 
mean arterial pressure, DBP; diastolic blood pressure, HR; heart rate, TG; triglyceride, TC; total cholesterol, LDL; 
low-density lipoprotein, VLDL; very low-density lipoprotein, HDL; high density lipoprotein; N/A, not applicable. 
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Figure 2: Possible mechanism of action of Tulbaghia violacea. The dark arrows indicate mechanisms already 
reported in literature, while the light arrows indicate proposed mechanisms. Increased (↑), decreased (↓), blood 
pressure (BP), angiotensin II (ang II), angiotensin II type 1 (AT1) receptor, reactive oxygen species (ROS), 
sympathetic nerve (SN), parasympathetic nerve (paraSN), stroke volume (SV), cardiac output (CO), heart rate 
(HR) 
 
may not directly inhibit the AT1 receptor. 
However, enhanced natriuresis has been 
reported with chronic treatment of DSS with T. 
violacea [22,32]. This was associated with down-
regulation of the AT1a  mRNA in one study [32], 
but was not associated with down-regulation of 
the AT1a mRNA in another [22] (Table 1, Figure 
2), which may suggest that the plant may 
produce its natriuretic action via other 
mechanisms or receptors, aside the AT1a. 
 
Aldosterone is a mineralocorticoid synthesized in 
the zona glomerulosa of the adrenal gland in 
response to ang II, adrenocorticotropin and 
potassium. It regulates electrolyte, fluid balance 
and BP homeostasis [40]. It also mediates 
maladaptive tissue remodelling throughout the 
cardiovascular and central nervous system. 
Primary hyperaldosteronism leads to a greater 
frequency of resistant HTN, as well as CVD and 
chronic kidney disease (CKD) morbidity and 
mortality, compared with essential HTN [41]. 
Reducing plasma aldosterone levels may be a 
third point of intervention of T. violacea in the 
RAAS, with inhibition of ACE and AT1a mRNA 
expression being the first and second 
respectively. Interestingly, chronic infusion of T. 
violacea resulted in  significant reduction (p < 
0.05) in plasma aldosterone levels in two studies 
in SHR [21] and DSS [32] (Table 1, Figure 2), but 
this reduction was not observed in a third study 
[22].  
Effects of TV on the autonomic nervous 
system 
 
The VSMCs are the major cellular component of 
the vascular media and mediate vasodilatation 
and vasoconstriction; and are innervated by both 
sympathetic and parasympathetic fibres [42]. The 
autonomic nervous system (ANS) consists of 
both the sympathetic and parasympathetic 
nervous systems, the activities of both systems 
are normally in dynamic balance, and plays a 
vital role in the control of cardiovascular activity 
[43]. Interestingly, a large proportion of patients 
with HTN have increased sympathetic activity, 
associated with decreased parasympathetic 
activity [44]. Adrenoceptors mediate the actions 
of the sympathetic nervous system [45]. 
Stimulation of the beta 1 (β1) adrenoceptors in 
the heart produces increases in heart rate (HR), 
cardiac output, and ultimately BP [46]. Inhibition 
of the β1 adreonoceptors by T. violacea may 
have contributed to the bradycardia, associated 
with reduction in BP observed in the SHR [11] 
(Table 1, Figure 2).  Resting HR is an 
independent predictor of both cardiovascular and 
“all-cause” mortality in men and women with or 
without a diagnosed CVD [45], therefore agents 
that can reduce HR are beneficial to the CVS. 
The neurotransmitter of the parasympathetic 
nervous system is acetylcholine, and it acts via 
nicotinic and muscarinic receptors. Activation of 
Raji et al 
Trop J Pharm Res, June 2015; 14(6): 1115  
 
the muscarinic receptors in the heart leads to 
bradycardia [47]. T. violacea may have an effect 
on the muscarinic receptors, since pre-treatment 
of SHR with atropine, blocked the bradycardia of 
its methanolic extract [21] (Table 1, Figure 2). 
 
Effects of TV on oxidative stress and 
haemostasis 
 
Oxidative stress, characterized by an imbalance 
between the generation of reactive oxygen 
species (ROS) and the capacity of the intrinsic 
antioxidant defense system, has been implicated 
in the pathogenesis of CVD, including HTN [39]. 
ROS are important as signaling molecules and 
are produced continuously from oxygen in cells 
to support normal cellular functions such as 
proliferation and migration [48,49], but may result 
in cell injury when excessively produced, and 
have been implicated in a host of pathological 
processes, including vascular hypertrophy and 
remodelling, HTN, inflammation and 
atherosclerosis [38,49]. The established 
therapeutics against atherosclerosis are largely 
focused on alleviating hypertension and 
hyperlipidaemia or controlling haemostasis to 
prevent thrombotic complications [50]. To this 
end, T. violacea has been reported to improve 
lipid profile [30]; and have both anti-oxidant 
[30,37], and anti-thrombotic [24,29] properties 
(Table 1, Figure 2). 
 
RECOMMENDATIONS 
 
The traditional use of T. violacea in the treatment 
of HTN may be encouraged, although further 
studies are required, to not only ascertain its 
safety and optimal dose, but to also isolate and 
remove constituents that may negate the potency 
of the anti-hypertensive constituent(s). It will also 
be crucial to investigate the effect of temperature 
on the active constituent(s), as well as the first 
pass metabolism, the bioavailability when taken 
orally, the rate of metabolism in the body, the 
distribution, the half life, toxicity and also the 
route(s) of elimination of its constituents. Finally, 
an assessment into its interaction with other 
herbs, drugs or food in both experimental 
animals and in clinical trials would be required. 
 
CONCLUSION 
 
Various studies have shown that T. violacea has 
a wide-ranging effect on the cardiovascular 
system by modulating the renin-angiotensin 
aldosterone system, the autonomic nervous 
system, oxidative stress and haemostasis. 
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